Metabolex is a privately held company founded to discover and develop therapeutics for diabetes. The company’s lead product, MBX-102, is a novel insulin sensitizer currently in Phase I clinical trials. Metabolex’s pipeline includes one product candidate in preclinical development, and three other programs optimizing lead drug candidates, one of which is partnered with Abbott Laboratories. Metabolex’s two drug target discovery programs have produced one of the world’s largest databases of diabetes-expressed genes. One of these programs, in insulin secretion, is partnered with Pfizer, Inc., and the other, in insulin resistance, is partnered with Yamanouchi Pharmaceuticals Co., Ltd.
|04/19/07||Series D||32M||Avonmore Developments, Vafer Investment Group, ReCap Holdings, LLC, BootStrapped by Vijay, Triple Point Capital, Notion Capital, NYC Seed, QED Investors, Donovan Group Holdings LLC, TEOK Inc., Ben Horowitz, Othman Laraki, Bill Lee, James Hong, Rogers Ventures, Matt Eldridge, Josh Merchant, Heather Ritchie, Marc Simoncini||Unknown|